Next Article in Journal
Frequent FOXA1-Activating Mutations in Extramammary Paget’s Disease
Next Article in Special Issue
The Landscape of Targeted Therapies in TNBC
Previous Article in Journal
Hypoxia and Macrophages Act in Concert Towards a Beneficial Outcome in Colon Cancer
Previous Article in Special Issue
Role of BET Inhibitors in Triple Negative Breast Cancers
Open AccessReview

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes

1
Division of Medical Oncology, Department of Precision Medicine, School of Medicine, “Luigi Vanvitelli” University of Campania, 80131 Naples, Italy
2
Cancer Research UK, Edinburgh Centre, MRC Institute Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK
3
IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(4), 819; https://doi.org/10.3390/cancers12040819
Received: 29 February 2020 / Revised: 19 March 2020 / Accepted: 27 March 2020 / Published: 29 March 2020
Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, although several escalation approaches have been evaluated to improve survival outcomes. The addition of platinum salts to standard neoadjuvant chemotherapy (NACT) remains controversial due to the lack of clear survival advantage, and the use of adjuvant capecitabine represents a valid treatment option in TNBC patients with residual disease after NACT. Recently, several clinical trials showed promising results through the use of poly ADP-ribose polymerase (PARP) inhibitors and by incorporating immunotherapy with chemotherapy, enriching treatment options beyond conventional cytotoxic agents. In this review, we provided an overview on the current standard of care and a comprehensive update of the recent advances in the management of early stage TNBC and focused on the latest emerging biomarkers and their clinical application to select the best therapeutic strategy in this hard-to-treat population. View Full-Text
Keywords: triple negative breast cancer; neo-(adjuvant); biomarkers; PARP inhibitors; immunotherapy triple negative breast cancer; neo-(adjuvant); biomarkers; PARP inhibitors; immunotherapy
MDPI and ACS Style

Diana, A.; Carlino, F.; Franzese, E.; Oikonomidou, O.; Criscitiello, C.; De Vita, F.; Ciardiello, F.; Orditura, M. Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. Cancers 2020, 12, 819. https://doi.org/10.3390/cancers12040819

AMA Style

Diana A, Carlino F, Franzese E, Oikonomidou O, Criscitiello C, De Vita F, Ciardiello F, Orditura M. Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. Cancers. 2020; 12(4):819. https://doi.org/10.3390/cancers12040819

Chicago/Turabian Style

Diana, Anna; Carlino, Francesca; Franzese, Elisena; Oikonomidou, Olga; Criscitiello, Carmen; De Vita, Ferdinando; Ciardiello, Fortunato; Orditura, Michele. 2020. "Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes" Cancers 12, no. 4: 819. https://doi.org/10.3390/cancers12040819

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop